Moment Estimation from Time Domain Electromagnetic Data von Vallée, Marc, Moussaoui, Mouhamed

Volltext

Inversion of airborne time‐domain electromagnetic data to a 1D structure using lateral constraints von Vallée, Marc A., Smith, Richard S.

Volltext

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study von STRYJEWSKI, Martin E, CHU, Vivian H, KITT, Michael M, COREY, G. Ralph, O'RIORDAN, William D, WARREN, Brian L, DUNBAR, Lala M, YOUNG, David M, VALLEE, Marc, FOWLER, Vance G, MORGANROTH, Joel, BARRIERE, Steven L

Volltext

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients von Patton, Heather M, Patel, Keyur, Behling, Cynthia, Bylund, David, Blatt, Lawrence M, Vallée, Marc, Heaton, Shanon, Conrad, Andrew, Pockros, Paul J, McHutchison, John G

Volltext

Simultaneous detection of As and Se in polyester resin skin phantoms von Gherase, Mihai R., Vallee, Marc E., Fleming, David E.B.

Volltext

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment von Ariceta, Gema, Dixon, Bradley P., Kim, Seong Heon, Kapur, Gaurav, Mauch, Teri, Ortiz, Stephan, Vallee, Marc, Denker, Andrew E., Kang, Hee Gyung, Greenbaum, Larry A., Lovell, Helen, Muff-Luett, Melissa, Malone, Kristin, Adeagbo, Oluwasegun, Wilkerson, Alexandria, Fraga, Gloria, Sarri, Scherezade, Cheong, Hae Il, Ahn, Yo Han, Han, Kyoung Hee

Volltext

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment von Rondeau, Eric, Scully, Marie, Ariceta, Gema, Barbour, Tom, Cataland, Spero, Heyne, Nils, Miyakawa, Yoshitaka, Ortiz, Stephan, Swenson, Eugene, Vallee, Marc, Yoon, Sung-Soo, Kavanagh, David, Haller, Hermann, Babu, Sunil, Broeders, Nilufer, Lietar, Nicole, Brown, Fiona, Campbell, Philip, Chowdhury, Paramit, Kasimatis, Theo, Cirami, Lino, Caroti, Leonardo, Antognoli, Guilia, Delmas, Yahsou, Dobronravov, Vladimir, Gaeckler, Anja, Garrouste, Cyril, Greenwood, Gregory, Griffin, Siân, Huang, Chiu-Ching, Chen, I-Ru, Huang, Susan, Kim, Jin Seok, La Manna, Gaetano, Comai, Giorgia, Cappuccilli, Maria, Le Quintrec, Moglie, Jeantet, Guillaume, Fumie, Iino, Luque, Yosu, Menne, Jan, Morelle, Johan, Goffin, Eric, Muhlfeld, Anja, Nagaraj, Shashi, Arepally, Gowthami, Oh, Doyeun, Okumi, Masayoshi, Terente, Manuel Praga, Gutierréz, Elena, Rodriguez, Paola, Provot, Francois, Schönermarck, Ulf, Fischereder, Michael, Terrada, Natalia Ramos, Seitz-Polski, Barbara, Favre, Guillaume, Boyer-Suavet, Sonia, Vinogradova, Maria, Kirsanova, Tatiana, Wong, Edwin K.S.

Volltext

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab von Tanaka, Kazuki, Adams, Brigitte, Aris, Alvaro Madrid, Fujita, Naoya, Ogawa, Masayo, Ortiz, Stephan, Vallee, Marc, Greenbaum, Larry A.

Volltext

The spatial and temporal characteristics of Pc3 geomagnetic activity over canada in 2000, as a guide to planning the times of aeromagnetic surveys von VALLEE, Marc A, NEWITT, Larry, MANN, Ian R, MOUSSAOUI, Mouhamed, DUMONT, Régis, KEATING, Pierre

Volltext

Efficacy and Safety of Ravulizumab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome Previously Treated with Eculizumab: 26-Week and 1-Year Data: PO2331 von Greenbaum, Larry A., Fujita, Naoya, Adams, Brigitte V., Aris, Alvaro Madrid, Ogawa, Masayo, Ortiz, Stephan, Vallee, Marc, Tanaka, Kazuki

Volltext

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment (vol 97, pg 1287,... von Rondeau, Eric, Scully, Marie, Ariceta, Gema, Barbour, Tom, Cataland, Spero, Heyne, Nils, Miyakawa, Yoshitaka, Ortiz, Stephan, Swenson, Eugene, Vallee, Marc, Yoon, Sung-Soo, Kavanagh, David, Haller, Hermann

Volltext

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab (Sep, 10.1007/s0... von Tanaka, Kazuki, Adams, Brigitte, Aris, Alvaro Madrid, Fujita, Naoya, Ogawa, Masayo, Ortiz, Stephan, Vallee, Marc, Greenbaum, Larry A.

Volltext

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment (vol 97, pg 1287,... von Rondeau, Eric, Scully, Marie, Ariceta, Gema, Barbour, Tom, Cataland, Spero, Heyne, Nils, Miyakawa, Yoshitaka, Ortiz, Stephan, Swenson, Eugene, Vallee, Marc, Yoon, Sung-Soo, Kavanagh, David, Haller, Hermann

Volltext

Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial) von Aronow, Herbert D., MD, MPH, Califf, Robert M., MD, Harrington, Robert A., MD, Vallee, Marc, MSc, Graffagnino, Carmelo, MD, Shuaib, Ashfaq, MD, Fitzgerald, Desmond J., MD, Easton, J. Donald, MD, Van de Werf, Frans, MD, PhD, Diener, Hans-Christoph, MD, PhD, Ferguson, James, MD, Koudstaal, Peter J., MD, PhD, Amarenco, Pierre, MD, Theroux, Pierre, MD, Davis, Stephen, MD, Topol, Eric J., MD

Volltext

FacetModeller: Software for manual creation, manipulation and analysis of 3D surface-based models von Lelièvre, Peter G., Carter-McAuslan, Angela E., Dunham, Michael W., Jones, Drew J., Nalepa, Mariella, Squires, Chelsea L., Tycholiz, Cassandra J., Vallée, Marc A., Farquharson, Colin G.

Volltext

MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor von Tap, William D., Wagner, Andrew J., Sharma, Maitreyi G., Vallee, Marc, Michenzie, Mary F., Sherman, Matthew L., Ruiz-Soto, Rodrigo, Stacchiotti, Silvia, van de Sande, Michiel A.J., Gelderblom, Hans

Volltext

Efficacy and Safety of Ravulizumab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome Naïve to Complement Inhibitor Treatment: 26-Week and 1-Year Data: PO2358 von Ariceta, Gema, Dixon, Bradley P., Kim, Seong heon, Kapur, Gaurav, Mauch, Teri Jo, Ortiz, Stephan, Vallee, Marc, Denker, Andrew E., Kang, Hee Gyung, Greenbaum, Larry A.

Volltext

SO054ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS von Barbour, Thomas, Scully, Marie, Ariceta, Gema, Cataland, Spero, Garlo, Katherine, Heyne, Nils, Miyakawa, Yoshitaka, Vallee, Marc, Luque, Yosu, Yoon, Sung-Soo, Menne, Jan, Kavanagh, David

Volltext

Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatme... von Ariceta, Gema, Dixon, Bradley P., Kim, Seong Heon, Kapur, Gaurav, Mauch, Teri, Ortiz, Stephan, Vallee, Marc, Denker, Andrew E., Kang, Hee Gyung, Greenbaum, Larry A., Lovell, Helen, Muff-Luett, Melissa, Malone, Kristin, Adeagbo, Oluwasegun, Wilkerson, Alexandria, Fraga, Gloria, Sarri, Scherezade, Cheong, Hae Il, Ahn, Yo Han, Han, Kyoung Hee, Wühl, Elke, Ardissino, Gianluigi, Capone, Valentina, Constantinescu, Alexandru, Boydstun, Ivy, Raafat, Reem, Mersha, Marezhe, Wandique-Rapalo, Belkis, Hataya, Hiroshi, Hamada, Terano, Rees, Lesley, Pose, Araceli Garcia, Pérez, Inés Vergara, Vilariño, Mercedes Cao, Adams, Brigitte, Nathalie, Tram

Volltext

Self-organizing maps for pseudo-lithological classification of 3D airborne electromagnetic, gravity gradiometry and magnetic inversions von Fraser, Stephen J., Wilson, Glenn A., Cox, Leif H., Čuma, Martin, Zhdanov, Michael S., Vallée, Marc A.

Volltext